Wyandotte Times

A study published in JAMA Network Open by KU Medical Center researchers explores cost discrepancies for a generic hepatitis B drug. 

The study found that although the cost pharmacies pay for the drug plummeted, the average cost to consumers actually increased.

“We're all told generic competition will drop prices for drugs, and patients will benefit. But that's absolutely not happening with this drug,” said Nathan C. Bahr, M.D., an author of the study and associate professor of Internal Medicine in the Division of Infectious Disease at the University of Kansas School of Medicine. 

_{Source: https://www.facebook.com/kumedicalcenter/posts/pfbid0X4czh932k4gVFF9e2N3Qghz9LmBNb9m4vJGxHRDsZhR6qRsALLzsiPhiD7L3MC9sl}